C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
C4 Therapeutics, Inc. (Nasdaq: CCCC), a clinical-stage biopharmaceutical company, announced its participation in a fireside chat at the Stifel 2023 Virtual Targeted Oncology Days. The event is scheduled for April 26, 2023, at 11:00 AM ET. C4T is focused on advancing targeted protein degradation science to develop small-molecule medicines aimed at transforming disease treatment. Through its innovative TORPEDO® platform, C4T is designing therapies that leverage the body’s protein recycling system to degrade disease-causing proteins, addressing challenges like drug resistance. A live webcast of the chat will be available on C4T's website, along with an archived replay for 30 days post-event.
- None.
- None.
WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that C4T management will participate in a fireside chat at the Stifel 2023 Virtual Targeted Oncology Days.
Fireside Chat Details:
Event: Stifel 2023 Virtual Targeted Oncology Days
Date/Time: Wednesday, April 26th, 2023 at 11:00 AM ET
A live webcast will be available on the Investors section of the company’s website at www.c4therapeutics.com. An archived replay of the webcast will be available for approximately 30 days following the live event.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines that harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. C4T is advancing multiple targeted oncology programs to the clinic and expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases. For more information, please visit www.c4therapeutics.com.
Investor Contact:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com
Media Contact:
Loraine Spreen
Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
FAQ
When is C4 Therapeutics participating in the Stifel 2023 Virtual Targeted Oncology Days?
What is the focus of C4 Therapeutics?
Where can I watch the C4 Therapeutics fireside chat?
What technology does C4 Therapeutics use for drug development?
What is the potential benefit of C4 Therapeutics' approach?
